CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery DiseaseThe DELFT (Drug Eluting stent for LeFT main) Registry
Emanuele Meliga, MD*, ,
Hector Manuel Garcia-Garcia, MD, MSc*,
Marco Valgimigli, MD, PhD ,
Alaide Chieffo, MD, PhD ,
Giuseppe Biondi-Zoccai, MD ,
Andrew O. Maree, MD||,
Stephen Cook, MD¶,
Lindsay Reardon, MD||,
Claudio Moretti, MD ,
Stefano De Servi, MD#,
Igor F. Palacios, MD, FACC||,
Stephen Windecker, MD¶,
Antonio Colombo, MD, FACC, FESC ,
Ron van Domburg, PhD*,
Imad Sheiban, MD and
Patrick W. Serruys, MD, PhD, FACC, FESC*,*
* Department of Interventional Cardiology, Erasmus Medical Centre, Erasmus University, Rotterdam, the Netherlands
Department of Interventional Cardiology, S. Giovanni Battista Hospital, University of Turin, Turin, Italy
Department of Interventional Cardiology, S. Anna Hospital, University of Ferrara, Ferrara, Italy
Department of Interventional Cardiology, S. Raffaele Hospital, Milan, Italy
|| Department of Interventional Cardiology, Massachusetts General Hospital, Boston, Massachusetts
¶ Department of Interventional Cardiology, University Hospital, Bern, Switzerland
# Department of Cardiovascular Diseases, Ospedale Civile di Legnano, Legnano (Milan) Italy.
Manuscript received November 6, 2007;
revised manuscript received February 28, 2008,
accepted March 4, 2008.
* Reprint requests and correspondence: Dr. Patrick W. Serruys, Director of the Interventional Cardiology Department, Thoraxcenter, Erasmus Medical Center, Erasmus University, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands. (Email: p.w.j.c.serruys{at}erasmusmc.nl).
Objectives: The purpose of this study was to investigate the long-term safety and efficacy of percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation for unprotected left main coronary artery (ULMCA) disease.
Background: Long-term clinical outcomes after DES implantation for ULMCA disease have not yet been ascertained.
Methods: From April 2002 to April 2004, 358 consecutive patients who underwent PCI with DES implantation for de novo lesions on ULMCA were retrospectively selected and analyzed in 7 European and U.S. tertiary care centers. No patients were excluded from the analysis, and all patients had a minimum follow-up of 3 years.
Results: Technical success rate was 100%. Procedural success rate was 89.6%. After 3 years, major adverse cardiovascular events (MACE)–free survival in the whole population was 73.5%. According to the Academic Research Consortium definitions, cardiac death occurred in 9.2% of patients, and reinfarction, target lesion revascularization (TLR), and target vessel revascularization (TVR) occurred in 8.6%, 5.8%, and 14.2% of patients, respectively. Definite stent thrombosis occurred in 2 patients (specifically at 0 and 439 days). In elective patients, the 3-year MACE-free survival was 74.2%, with mortality, reinfarction, TLR, and TVR rates of 6.2%, 8.3%, 6.6%, and 16%, respectively. In the emergent group the 3-year MACE-free survival was 68.2%, with mortality, reinfarction, TLR, and TVR rates of 21.4%, 10%, 2.8%, and 7.1%, respectively.
Conclusions: Routine DES implantation in ULMCA disease seems encouraging, with favorable long-term clinical results.
|
Abbreviations and Acronyms
| | AMI = acute myocardial infarction | | BMS = bare-metal stent(s) | | CABG = coronary artery bypass grafting | | CD = cardiac death | | DES = drug-eluting stent(s) | | EF = ejection fraction | | EuroSCORE = European System for Cardiac Operative Risk Evaluation | | HI = hemodynamic instability | | IDDM = insulin-dependent diabetes mellitus | | MACE = major adverse cardiac event(s) | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | PES = paclitaxel-eluting stent(s) | | SES = sirolimus-eluting stent(s) | | ST = stent thrombosis | | TLR = target lesion revascularization | | TVR = target vessel revascularization | | ULMCA = unprotected left main coronary artery |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A31-A32.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
T. Palmerini, D. Sangiorgi, A. Marzocchi, C. Tamburino, I. Sheiban, M. Margheri, G. Vecchi, G. Sangiorgi, M. Ruffini, A. L. Bartorelli, et al.
Ostial and midshaft lesions vs. bifurcation lesions in 1111 patients with unprotected left main coronary artery stenosis treated with drug-eluting stents: results of the survey from the Italian Society of Invasive Cardiology
Eur. Heart J.,
June 9, 2009;
(2009)
ehp223v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2080 - 2097.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Alfonso
Left main coronary artery stenting crossing the rubicon.
J. Am. Coll. Cardiol.,
May 12, 2009;
53(19):
1769 - 1772.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Vaquerizo, T. Lefevre, O. Darremont, M. Silvestri, Y. Louvard, J. L. Leymarie, P. Garot, H. Routledge, F. de Marco, T. Unterseeh, et al.
Unprotected Left Main Stenting in the Real World: Two-Year Outcomes of the French Left Main Taxus Registry
Circulation,
May 5, 2009;
119(17):
2349 - 2356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-J. Park and D.-W. Park
Percutaneous Coronary Intervention With Stent Implantation Versus Coronary Artery Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Is It Time to Change Guidelines?
Circ Cardiovasc Intervent,
February 1, 2009;
2(1):
59 - 68.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008.
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Meliga, A. O. Maree, H. M. Garcia-Garcia, and P. W. Serruys
Reply
J. Am. Coll. Cardiol.,
November 11, 2008;
52(20):
1681 - 1681.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Taggart
The DELFT (Drug Eluting stent for LeFT main) Registry: The Unknowns
J. Am. Coll. Cardiol.,
November 11, 2008;
52(20):
1680 - 1681.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Hamdalla and D. J. Moliterno
Late drug-eluting stent thrombosis in unprotected left main coronary artery lesions--sometimes possible, but rarely definite or probable
Eur. Heart J.,
September 1, 2008;
29(17):
2064 - 2066.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Meliga, M. Valgimigli, P. Buszman, and P. W. Serruys
Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Disease: The Endless Debate
J. Am. Coll. Cardiol.,
August 12, 2008;
52(7):
582 - 584.
[Full Text]
[PDF]
|
 |
|
|